FDA approves ofatumumab for the treatment of relapsing forms of multiple sclerosis
The US FDA has approved ofatumumab for the treatment of clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It can be self-administered once monthly via the Sensoready® autoinjector pen.
Source:
Biospace Inc.
SPS commentary:
Ofatumumab is a fully humanised, high affinity monoclonal antibody targeted against CD20 cell surface antigen of B-cell membranes. An application for its approval in the EU was filed in February 2020.